Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supporting once monthly or less frequent administration. -As previously disclosed, oral tablet formulation of small molecule ASC30 demonstrated potentially best-in-class 6.3% weight loss in patients with obesity after a four-week treatment. Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) today announces […]

(NASDAQ:ACON),(NASDAQ:ACONW), Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements Pivotal CLARITY trial fully funded with initial interim results expected in Q2 2026 BROOMFIELD, Colo., March 31, 2025

(NASDAQ:VFF), – Former consumer goods distribution, food, and retail service industry executive will help guide the Company's global expansion initiatives – VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced the hiring of Yvonne Trupiano as the Company's Executive Vice President and

(NASDAQ:KSPI), ALMATY, Kazakhstan, March 31, 2025 (GLOBE NEWSWIRE) — Joint Stock Company Kaspi.kz (Nasdaq: KSPI) announces that the following resolutions were duly passed at its Annual General Meeting on 28 March 2025: To approve the agenda of the Annual General Meeting of Shareholders of JSC Kaspi.kz: Approval of the agenda; Approval of JSC Kaspi.kz's 2024

(NASDAQ:LMFA), – Fourth quarter and full-year 2024 total revenue of $2.0 million and $11.0 million, respectively.– Fourth quarter and full-year 2024 CORE EBITDA of $3.3 million and $3.9 million, respectively.– Held 165.8 Bitcoin on February 28, 2025 valued at approximately $14.4 million, as of March 26, 2025 TAMPA, Fla., March 31, 2025 (GLOBE NEWSWIRE) —

(NASDAQ:PCVX), — At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20(R) (PCV20) — — At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses — —

(NASDAQ:UNCY), – Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 – Commercial planning in preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) —

(NASDAQ:GYRE), SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical Products Administration (NMPA) of the People's Republic of China (“PRC”) has approved its clinical trial application for a potential new indication for pirfenidone in oncology-related pulmonary

TORONTO, ON, March 31, 2025 (GLOBE NEWSWIRE) — This Earth Month, two feel-good icons have teamed up to drive Canadians to make small steps for the good of the planet: Bonterra, the innovative and sustainably focused line of household paper products, and Volkswagen, the creator of the iconic Volkswagen microbus, have joined forces for the

(NASDAQ:PMN), Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, March 31, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology